Loading
Life sciences · Preprint
arXiv · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Preprint.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Recent work characterizes the Adam optimizer as sign descent modulated by gradient uncertainty: the update is the sign of the batch gradient, scaled by how strongly the batch supports that sign. We apply this view directly and introduce ZEMA (Z-score Evidence Momentum Adaptation), which measures that support with a per-coordinate $z$-score computed from the per-example gradients in the current batch, converts it into a sign probability, and smooths the resulting update with a single exponential moving average. Because the probability is formed before smoothing rather than after, ZEMA keeps one state per parameter instead of Adam's two, at a $4.6$ increase in per-step time; the per-example variance it requires can also be estimated from a small fraction of the batch. In fine-tuning and pretraining experiments, ZEMA is competitive with Adam, reduces the variability of the validation loss, and in some settings recovers the sign of the full-dataset gradient more consistently. We close with two directions this opens: extending confidence adaptation beyond the sign geometry, to methods such as Muon, and to differentially private training.